Top Abstract Purchase Related
Home
>
Node
>
Subnode

DNA topoisomerase inhibitor

Hino, M.; Niitani, H.

Nihon Rinsho. Japanese Journal of Clinical Medicine 51(12): 3291-3300

1993

ISSN/ISBN: 0047-1852
PMID: 8283648
Document Number: 419617
DNA topoisomerases are enzymes involved in various aspects of genetic processes by catalyzing a topological change of DNA. Topoisomerase is now viewed as an important cellular target of antitumor drugs. These drugs targeting topoisomerase have been used to establish a relationship between drug-induced cleavable complex formation and cytotoxicity. Topoisomerase I is shown to be the cellular target of camptothecin and its derivatives. And topoisomerase II targeting drugs are both intercalative drugs (acridines, ellipticines, anthracyclines) and non-intercalative drugs (epipodophyllotoxin derivatives). And then Irinotecan, topotecan, sobuzoxane and IST-622 are unique topoisomerase inhibitors and are under investigation in Japan, the new antitumor drugs targeting topoisomerases are reviewed.

Document emailed within 1 workday
Secure & encrypted payments

Sugiura, T.; Ariyoshi, Y. 1992: DNA topoisomerase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(13): 2140-2145
Suzuki, K.; Yahara, S.; Maehata, K.; Uyeda, M. 2001: Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba Journal of Natural Products 64(2): 204-207
Weisenberger, D.; Scheer, U.; Benavente, R. 1993: The DNA topoisomerase I inhibitor camptothecin blocks postmitotic reformation of nucleoli in mammalian cells European Journal of Cell Biology 61(1): 189-192
Douc-Rasy, S.; Kayser, A.; Riou, G. 1983: A specific inhibitor of type I DNA-topoisomerase of Trypanosoma cruzi: dimethyl-hydroxy-ellipticinium Biochemical and Biophysical Research Communications 117(1): 1-5
Oguro, M.; Seki, Y. 1991: Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(10): 1556-1561
Oizumi, S.; Isobe, H.; Ogura, S.; Ishida, T.; Yamazaki, K.; Nishimura, M.; Kawakami, Y.; Dosaka-Akita, H. 2002: Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells Anticancer Research 22(6c): 4029-4037
Strel'tsov, S.A.; Mikheĭkin, A.L.; Grokhovskiĭ, S.L.; Oleĭnikov, V.A.; Zhuze, A.L. 2002: Interaction of topotecan, DNA topoisomerase i inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove Molekuliarnaia Biologiia 36(3): 511-524
Ling, Y.H.; Xu, B. 1993: Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells Zhongguo Yao Li Xue Bao 14(6): 546-550
Yu, N.Y.; Conway, C.; Pena, R.L.S.; Chen, J.Y. 2007: STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models Anticancer Research 27(4B): 2541-2545
Lee, F.Y.; Flannery, D.J.; Siemann, D.W. 1992: Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II Cancer Research 52(13): 3515-3520
Bucior, J.; Ziółko, E.; Tomczyk, A.; Sosada, K.; Knopik, J.; Kempiński, M. 2004: Effect of palliative chemotherapy with topoisomerase inhibitor on the quality of life and survival of patients with advanced colorectal carcinoma Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 17(101): 457-462
Sehested, M.; Wessel, I.; Jensen, L.H.; Holm, B.; Oliveri, R.S.; Kenwrick, S.; Creighton, A.M.; Nitiss, J.L.; Jensen, P.B. 1998: Chinese hamster ovary cells resistant to the topoisomerase Ii catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines Cancer Research 58(7): 1460-1468
Strel'tsov, S.A.; Mikheĭkin, A.L.; Nechipurenko, I.D. 2001: Interaction of topotecan--a DNA topoisomerase i inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan Molekuliarnaia Biologiia 35(3): 442-450
Coleman, L.W.; Bronstein, I.B.; Holden, J.A. 2001: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas Anticancer Research 21(2a): 1167-1172
Herzog, C.E.; Holmes, K.A.; Tuschong, L.M.; Ganapathi, R.; Zwelling, L.A. 1998: Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha Cancer Research 58(23): 5298-5300
Harker, W.G.; Slade, D.L.; Parr, R.L.; Feldhoff, P.W.; Sullivan, D.M.; Holguin, M.H. 1995: Alterations in the topoisomerase Ii alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase Ii beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Research 55(8): 1707-1716
Laurell, M.; Stenflo, J. 1989: Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein Thrombosis and Haemostasis 62(3): 885-891
Khan, N.A.; Havouis, R.; Quemener, V.; Moulinoux, J.P. 1992: Protein kinase C inhibitor (H-7) potentiates antiproliferative effects of a polyamine biosynthesis inhibitor Anticancer Research 12(4): 1223-1226
Depré, M.; Van Hecken, A.; Verbesselt, R.; De Lepeleire, I.; Schwartz, J.; Porras, A.; Larson, P.; Lin, C.; De Schepper, P.J. 1998: Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man International Journal of Clinical Pharmacology Research 18(2): 53-61
Bolten, W.W. 2003: In high risk patients cyclooxygenase inhibitor plus proton pump inhibitor MMW Fortschritte der Medizin 145(5): 9